Long-Term Efficacy and Safety of Lebrikizumab Is Maintained in Patients With Moderate-to-Severe ​ Atopic Dermatitis: Results Up to 3 Years From ADjoin. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 1, p. s510, 2025. DOI: 10.25251/skin.9.supp.510. Disponível em: https://skin.dermsquared.com/skin/article/view/3153. Acesso em: 17 apr. 2026.